Regulatory Considerations for Additively Manufactured Implants

Additive manufacturing (AM) has moved well beyond experimental use and is now a routine production method for many orthopedic implants. Spinal interbody devices, trauma implants, and joint reconstruction components increasingly rely on AM to enable complex geometries, internal lattices, and surface features that are difficult or impossible to achieve with conventional manufacturing techniques. But as adoption has grown, so has regulatory scrutiny.

Although the U.S. Food and Drug Administration (FDA) does not regulate AM as a standalone technology category, AM-produced implants are often reviewed more closely than their traditionally manufactured counterparts. For load-bearing, long-term implants, performance cannot be separated from the process used to create the device. Thus, regulatory success requires manufacturers to demonstrate not only that an implant is safe and effective, but that the AM workflow used to produce it is well understood, properly controlled, and consistently executed.

Regulatory Pathways and FDA’s Risk-Based Focus

From a regulatory standpoint, AM implants follow the same statutory pathways—most commonly a 510(k) or PMA—as traditionally manufactured devices. FDA continues to remind sponsors that the use of AM alone does not dictate regulatory classification or pathway selection. Nevertheless, AM-enabled design features such as novel porous architectures, patient-specific geometries, or highly anisotropic material behavior can introduce new safety or effectiveness questions that must be addressed.

FDA’s guidance document, “Technical Considerations for Additive Manufactured Medical Devices,” provides a useful framework for navigating these issues. For implants, the Agency views AM risk through a process-centric lens. Mechanical performance, biological response, and long-term durability are directly influenced by printer behavior, material state, and post-processing steps. Successful submissions identify AM-specific risks, verify the success of mitigation measures, and validate their consistency, thus aligning with FDA’s risk-based review.

Design Controls and Implant Design Space

For AM implants, “design” extends far beyond a traditional engineering drawing. FDA considers the design to include the entire digital workflow: CAD models, lattice definitions, design automation rules, build preparation software, and any constraints applied to size-variant or patient-matched devices.

Manufacturers are expected to define a validated design envelope that bounds all permissible device configurations. For lattice-based implants, FDA reviewers commonly focus on how parameters such as pore size, strut thickness, porosity gradients, and surface morphology influence compressive strength, fatigue life, and subsidence risk. Clearly identifying and testing worst-case geometries remains a regulatory best practice.

This expectation becomes even more important for patient-matched implants. In these cases, FDA advises manufacturers to show that imaging inputs, segmentation, and automated design rules consistently produce devices that remain within the validated design envelope regardless of anatomical variability.

Manufacturing Process Characterization

FDA increasingly requires submissions to include a clear, structured description of the AM workflow. This is often best presented as a concise, executive-level overview that explains how digital design inputs are translated into printed implants.

Reviewers typically want clarity on several points early in their assessment:

• Which AM system or systems are used to fabricate the device
• Whether printers are stock OEM configurations or customized platforms
• How many machines are used in production, and how consistency is ensured
• Whether build files are fixed (“locked”) or re-sliced for each print
• How worst-case configurations are identified across systems, locations, and orientations

Even printers of the same make and model can exhibit different performance characteristics from each other and over time. In practice, FDA reviewers often ask how manufacturers establish equivalence across machines or define a conservative worst-case system for validation.

Process Validation and Critical Parameters

AM processes, particularly powder bed fusion and material extrusion, are inherently sensitive to input parameters. Laser power, scan speed, layer thickness, extrusion temperature, nozzle condition, and build path strategy can all affect porosity, microstructure, anisotropy, and defect formation.

FDA expects manufacturers to identify which parameters materially affect critical device characteristics and to challenge those parameters during process validation. Submissions should demonstrate that selected parameter ranges consistently produce devices meeting dimensional, mechanical, and material performance requirements.

Where available, long-term monitoring data can significantly strengthen a submission. Trending dimensional accuracy or mechanical properties of verification coupons over time helps demonstrate process stability and provides confidence that untested worst-case conditions are unlikely to emerge post-market.

Materials, Feedstock, and Reuse Controls

Material control is a central focus during FDA review of AM implants. For metallic powders and thermoplastic filaments, FDA typically requests detailed information on material specifications, supplier qualification, storage conditions, and acceptance criteria.

Material reuse—whether powder recycling or thermally cycled polymers—is an inherent cost-saving feature of AM but frequently attracts additional questions. Manufacturers should clearly define reuse limits, monitoring strategies, and objective rejection criteria. Just as important, submissions should demonstrate that reuse does not introduce a new worst-case condition by altering chemistry, particle size distribution, or contamination risk.

Post-Processing as a Critical Manufacturing Step

For most AM implants, post-processing is not optional. Heat treatment, hot isostatic pressing (HIP), machining, surface finishing, and cleaning are integral steps that directly influence device performance and biocompatibility. FDA treats these steps as part of the manufacturing process itself. Additionally, biocompatibility remains a cornerstone of implant regulation, and AM introduces new variability and lifecycle considerations that extend beyond premarket testing. FDA’s guidance document, “Use of International Standard ISO 10993-1, Biological Evaluation of Medical Devices,” emphasizes that biocompatibility evaluations should reflect the final finished device, including manufacturing and post-processing effects. Therefore, changes in materials, processes, or post-processing may necessitate both biocompatibility and mechanical reassessment.

Validation should demonstrate that post-processing yields consistent mechanical properties, surface characteristics, and dimensional accuracy. For implants with articulating surfaces, machining and finishing processes require particular scrutiny to ensure predictable wear and corrosion performance.

Verification, Inspection, and Residual Risks

AM implants often incorporate internal features that cannot be inspected using traditional methods. FDA acknowledges these limitations but requires manufacturers to offset them with strong process controls and verification strategies.

Verification activities, such as coupon testing, dimensional monitoring, and mechanical screening, should be clearly defined, including test frequency and acceptance criteria. Reviewers frequently warn against relying solely on generic material specification minimums, such as the tensile properties outlined in ASTM F3001, which may not reflect the validated performance state of the final finished device. 

For material extrusion systems, FDA has highlighted potential risks associated with manufacturing residues, including degraded polymers, support materials, or equipment-related contaminants. Submissions should explain how these risks are identified, mitigated, and verified in the final finished device.

Managing Change Over the Device Lifecycle

AM technologies evolve quickly, but implants demand conservative change management. FDA expects manufacturers to evaluate whether changes to equipment, software, materials, or process parameters remain within the validated design and manufacturing envelope.

Early engagement through FDA’s Q-Submission program remains a practical strategy, particularly when introducing new AM features, expanding printer fleets, or implementing post-market manufacturing changes that could influence device performance, as such changes have the potential to move the process outside the validated envelope.

Conclusion

Additive manufacturing has enabled meaningful innovation in implant design and performance, but it has also raised FDA’s expectations for process understanding, validation, and lifecycle control. For implant manufacturers, regulatory success depends on demonstrating consistent control over design variability, materials, manufacturing processes, and change management.

When AM-specific considerations are thoughtfully aligned with FDA’s established risk-based and quality system principles, manufacturers are better positioned for both an efficient review and for sustaining long-term safety and performance once devices reach the market.

MORE FROM MCRA: How FDA’s BDD Can Streamline Reimbursement

Ethan Naylor is a vice president of Regulatory Affairs at MCRA, an IQVIA business. He is focused primarily on U.S. regulatory submissions for spinal medical devices. Naylor helps clients with FDA regulatory strategies and submission support, including pre-submissions for non-clinical and clinical data development, 510(k)s, Breakthrough Device Designations, De Novo classification requests, and premarket approvals. Before joining MCRA, Naylor worked for nearly six years at the FDA, where he was an assistant director, a policy analyst in the 510(k) staff office, and a lead reviewer in the Spine Division. He earned a master of science degree in biomedical engineering from Johns Hopkins University and a bachelor of science degree in biochemistry from Indiana Wesleyan University.